Btk
Bruton tyrosine kinase
Bruton tyrosine kinase (Btk) is a member of the Tec family kinases with a well-characterized role in B-cell antigen receptor (BCR)-signaling and B-cell activation.
Btk plays a crucial role in B cell development and activation through the BCR signaling pathway and represents a new target for diseases characterized by inappropriate B cell activity. Btk is a kinase expressed exclusively in B cells and myeloid cells and has a well characterized, vital role in B cells highlighted by the human primary immune deficiency disease, X-linked agammaglobulinemia (XLA), which results from mutation in the Btk gene. Btk plays an essential role in the BCR signaling pathway. Antigen binding to the BCR results in B cell receptor oligomerization, Syk and Lyn kinase activation, followed by Btk kinase activation. Once activated, Btk forms a signaling complex with proteins such as BLNK, Lyn, and Syk and phosphorylates phospholipase C (PLC)γ2. This leads to downstream release of intracellular Ca2+ stores and propagation of the BCR signaling pathway through extracellular signal-regulated kinase and NF-κB signaling, ultimately resulting in transcriptional changes to foster B cell survival, proliferation, and/or differentiation.
All Product Categories
-
Btk Related Products (271)
Related Products (271)
-
Recombinant Proteins (19)
-
Antibodies (3)
-
JAK3/BTK-IN-1
0 ImagesCat. No.: HY-143716CAS No.: 2674036-91-8JAK3/BTK-IN-1 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-1 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147952A1, compound 002).
-
PCI-33380 (Standard)
0 ImagesCat. No.: HY-100335RCAS No.: 1022899-36-0PCI-33380 (Standard) is the analytical standard of PCI-33380 (HY-100335). This product is intended for research and analytical applications. PCI-33380 is a fluorescent probe ( (Ex=532 nm, Em=555 nm). PCI-33380 consists of a (BTK) inhibitor PCI-32765 (HY-10997) attaching with a Bodipy-FL fluorophore via a piperazine linker. PCI-33380 binds predominantly to Btk in B cell lysates with cell permeable activity. PCI-33380 can be used for imaging live cancer cells such as non-Hodgkin lymphoma research
-
BMS-935177 (Standard)
0 ImagesCat. No.: HY-101793RCAS No.: 1231889-53-4BMS-935177 (Standard) is the analytical standard of BMS-935177 (HY-101793). This product is intended for research and analytical applications. BMS-935177 is a potent and selective reversible inhibitor of Bruton’s tyrosine kinase (Btk) with an IC50 of 3 nM.
-
Poseltinib (Standard)
0 ImagesCat. No.: HY-109010RCAS No.: 1353552-97-2Synonyms: HM71224 (Standard); LY3337641 (Standard)Poseltinib (Standard) is the analytical standard of Poseltinib (HY-109010). This product is intended for research and analytical applications. Poseltinib (HM71224) is an orally active, selective, irreversible small molecule Bruton tyrosine Kinase (BTK) inhibitor. With an IC50 of 1.95 nM. Poseltinib effectively inhibits the signaling mediated by B cell receptors (BCR), Fc receptors (FcR), and Toll-like receptors (TLR). Poseltinib has anti-inflammatory activity and can be used in the research of rheumatoid arthritis.
-
(±)-Zanubrutinib (Standard)
0 ImagesCat. No.: HY-101474RCAS No.: 1633350-06-7Synonyms: (±)-BGB-3111 (Standard)(±)-Zanubrutinib (Standard) is the analytical standard of (±)-Zanubrutinib (HY-101474). This product is intended for research and analytical applications. (±)-Zanubrutinib ((±)-BGB-3111) is the racemate of Zanubrutinib (HY-101474A). (±)-Zanubrutinib inhibits Bruton's tyrosine kinase (Btk) with an IC50 of 0.63 nM.
-
(Rac)-IBT6A hydrochloride
0 ImagesCat. No.: HY-13036CCAS No.: 1807619-60-8(Rac)-IBT6A hydrochloride is a racemate of IBT6A hydrochloride. IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM.
-
BTK IN-1 (Standard)
0 ImagesCat. No.: HY-101941RCAS No.: 1270014-40-8Synonyms: SNS062 analog (Standard)
-
Elsubrutinib (Standard)
0 ImagesCat. No.: HY-109143RCAS No.: 1643570-24-4Synonyms: ABBV-105 (Standard)Elsubrutinib (Standard) is the analytical standard of Elsubrutinib (HY-109143). This product is intended for research and analytical applications. Elsubrutinib (ABBV-105) is an orally active, potent, selective and irreversible Bruton's tyrosine Kinase (BTK) inhibitor. The IC50 of Elsubrutinib for BTK catalytic domain is 0.18 μM. Elsubrutinib can be used for the research of inflammatory disease.
-
(R,R)-Birelentinib
0 ImagesCat. No.: HY-160167ACAS No.: 2662512-14-1Synonyms: (R,R)-DZD8586(R,R)-Birelentinib ((R,R)-DZD8586) (Compound 14) is a potent BTK inhibitor with IC50 values for BTK WT and BTK C481S of 0.7 and 0.86 nM, respectively. (R,R)-Birelentinib inhibits the self-phosphorylation of BTK and its IC50 is 24.3 nM. (R,R)-Birelentinib exhibits significant anti-proliferative activity against wild-type and C481S mutant HEK293 cells. (R,R)-Birelentinib can be used for the study of drug-resistant B-cell malignancies.
-
Vecabrutinib (Standard)
0 ImagesCat. No.: HY-109078RCAS No.: 1510829-06-7Synonyms: SNS-062 (Standard)Vecabrutinib (Standard) is the analytical standard of Vecabrutinib (HY-109078). This product is intended for research and analytical applications. Vecabrutinib (SNS-062) is a potent, noncovalent BTK and ITK inhibitor, with Kd values of 0.3 nM and 2.2 nM, respectively. Vecabrutinib shows an IC50 of 24 nM for ITK.
-
Avitinib dihydrochloride
0 ImagesCat. No.: HY-183397CAS No.: 1557268-90-2Synonyms: Abivertinib dihydrochloride; AC0010 dihydrochlorideAvitinib (Abivertinib) dihydrochloride is a third-generation, irreversible and orally active selective EGFR inhibitor, with IC50 values of 0.18 nM, 0.18 nM, 7.68 nM and against EGFR L858R, EGFR T790M and wild-type EGFR. Avitinib dihydrochloride is also a BTK inhibitor that induces apoptosis and inhibits phosphorylation of BTK in mantle cell lymphoma. Avitinib dihydrochloride shows anticancer effects.
-
PF-06465469 (Standard)
0 ImagesCat. No.: HY-108691RCAS No.: 1407966-77-1PF-06465469 (Standard) is the analytical standard of PF-06465469 (HY-108691). This product is intended for research and analytical applications. PF-06465469 is a covalent inhibitor of ITK with an IC50 of 2 nM. PF-06465469 also inhibits BTK. PF-06465469 inhibits cell migration in response to CXCL12. PF-06465469 decreases PD-1 and LAG-3 expression. PF-06465469 can be used to study leukemia and T-cell lymphoma.
-
(R)-Elsubrutinib (Standard)
0 ImagesCat. No.: HY-109143BRCAS No.: 1643570-23-3Synonyms: (R)-ABBV-105 (Standard)(R)-Elsubrutinib (Standard) is the analytical standard of (R)-Elsubrutinib (HY-109143B). This product is intended for research and analytical applications. (R)-Elsubrutinib ((R)-ABBV-105) is a Btk inhibitor. (R)-Elsubrutinib can be used in studies of immune diseases (such as rheumatoid arthritis, psoriasis, ankylosing spondylitis, asthma, systemic lupus erythematosus) and cancer.
-
Evobrutinib (Standard)
0 ImagesCat. No.: HY-101215RCAS No.: 1415823-73-2Synonyms: M2951 (Standard); MSC2364447C (Standard)Evobrutinib (Standard) is the analytical standard of Evobrutinib (HY-101215). This product is intended for research and analytical applications. Evobrutinib (M2951) is an orally active, potent, highly selective and irreversibly covalent BTK inhibitor, with an IC50 of 8.9 nM. Evobrutinib (M2951) can be used for the research of autoimmune diseases.
-
ACP-5862-d4
0 ImagesCat. No.: HY-135334SACP-5862-d4 is deuterium labeled ACP-5862. ACP-5862 is a major active, circulating, pyrrolidine ring-opened metabolite of Acalabrutinib with an IC50 of 5.0 nM for Bruton tyrosine kinase (BTK). ACP‐5862 is a weak time‐dependent inactivator of CYP3A4 and CYP2C8. Acalabrutinib is an orally active, irreversible, and highly selective BTK inhibitor, with an IC50 of 3 nM and EC50 of 8 nM.
-
Btk inhibitor 2 (Standard)
0 ImagesCat. No.: HY-101766RCAS No.: 1558036-85-3
-
Tolebrutinib (Standard)
0 ImagesCat. No.: HY-109192RCAS No.: 1971920-73-6Synonyms: SAR442168 (Standard); PRN2246 (Standard)Tolebrutinib (SAR442168) (Standard) is the analytical standard of Tolebrutinib (HY-109192). This product is intended for research and analytical applications. Tolebrutinib (SAR442168) is an orally active, selective, and blood-brain barrier-penetrant BTK inhibitor with neuroactive properties. Tolebrutinib is being investigated for use in multiple sclerosis (MS), particularly secondary progressive multiple sclerosis (SPMS).
-
Spebrutinib besylate
0 ImagesCat. No.: HY-18012ACAS No.: 1360053-81-1Synonyms: AVL-292 benzenesulfonate; CC-292 besylateSpebrutinib besylate (AVL-292 benzenesulfonate; CC-292 besylate) is a potent inhibitor of Btk kinase activity (IC50<0.5 nM, Kinact/Ki=7.69×104 M-1s-1s) in biochemical assays.
-
BMS-986142 (Standard)
0 ImagesCat. No.: HY-101856RCAS No.: 1643368-58-4BMS-986142 (Standard) is the analytical standard of BMS-986142 (HY-101856). This product is intended for research and analytical applications. BMS-986142 is a potent and highly selective reversible inhibitor of Bruton's tyrosine kinase (BTK) with an IC50 of 0.5 nM.
